RNA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.0%, SMA50 0.42%, SMA200 38.79%). The stock’s 14-day RSI is 57.58 (neutral), while the ATR of 0.22 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.36% below its high and over 238.45% above its low. Average 10-day trading volume of 4.65 million shares is significantly above the 3-month average of 2.23 million, indicating heightened recent market interest.

Avidity Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.91. This means the shares are trading below this model’s fair value.

Avidity Biosciences, Inc. (NASDAQ:RNA) closed at $72.80 USD, gaining $0.05 (0.07%) from the previous close of $72.75. The stock is currently trading near its 52-week high $21.51 and $73.06. With a market capitalization of about $11.25 billion, Avidity Biosciences, Inc. is classified as a large-cap and shows market-like volatility (beta ~0.93). Key stats such as the average daily volume over the past year has been around 2.23 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Avidity Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Sarah Boyce, the company employs approximately 391 people and listed since June 12, 2020. Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.

Avidity Biosciences, Inc. generated EPS of -$4.96 over the past year. Five-year average earnings growth is -19.41%. Wall Street analysts project EPS growth of -11.51% annually over the next five years. The latest quarter delivered EPS of -$1.27. The next quarter is forecast at -$1.32. Next year's EPS is expected at -$28.91. Analyst sentiment is bullish. Analyst rating data shows there are 8 Strong Buy ratings, 16 Buy ratings, 9 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $96.00 to $48.00. The high target offers 31.87% upside. The low target suggests -34.07% downside. The mean target is $68.03. This offers -6.55% upside. Avidity Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 20.95%. The prior quarter beat by 27.37%. Over the last six quarters, Apple has recorded several small beats. These include -14.47% in August 09, 2024.

Avidity Biosciences, Inc. has 128.65 million shares outstanding. The public float is 98.07 million shares, elevated short interest at 12.71% of float. This equals 16.21 million shares. The short ratio is 6.27 days. Institutional investors hold 112.81% of the float. Insiders own 4.79%. RTW INVESTMENTS, LP holds 4.80 million shares, Cormorant Asset Management, LP has 2.51 million shares and Boyce Sarah has 269.01 thousand shares. Over the past six months, insider transactions show net selling. They sold 207.01 thousand shares across 25 transactions.

Avidity Biosciences, Inc. trades at a P/E ratio of -14.63, slightly below the S&P 500 average, with a price-to-sales ratio of 599.21 and a price-to-book ratio of 5.93 trading at moderately above to book value. The P/FCF stands at -16.85, also below market averages.

Our AI price prediction model suggests that Avidity Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -28.65%, reaching $51.94 by May 26, 2026, with a range of $48.49 to $54.83. 1-Year Outlook: Projected gain of 26.99%, with price at $92.45 by February 25, 2027, within a range of $87.07 to $96.37.

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are flat 0.47% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Avidity Biosciences, Inc. trading at a premium to the broader market with a P/E of -14.63. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $58.41, suggesting -19.77% downside.